CN114392229A - 一种抑制角膜基质纤维化的温敏性水凝胶及其制备方法 - Google Patents
一种抑制角膜基质纤维化的温敏性水凝胶及其制备方法 Download PDFInfo
- Publication number
- CN114392229A CN114392229A CN202210013121.4A CN202210013121A CN114392229A CN 114392229 A CN114392229 A CN 114392229A CN 202210013121 A CN202210013121 A CN 202210013121A CN 114392229 A CN114392229 A CN 114392229A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- temperature
- sensitive
- tripterine
- sensitive hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 66
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 33
- 230000004761 fibrosis Effects 0.000 title claims abstract description 33
- 210000003683 corneal stroma Anatomy 0.000 title claims abstract description 23
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims abstract description 53
- 229920000642 polymer Polymers 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 239000000693 micelle Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 239000003960 organic solvent Substances 0.000 claims abstract description 12
- 239000008215 water for injection Substances 0.000 claims abstract description 11
- 239000011259 mixed solution Substances 0.000 claims abstract description 10
- 239000004698 Polyethylene Substances 0.000 claims abstract description 8
- 229940072106 hydroxystearate Drugs 0.000 claims abstract description 8
- -1 polyethylene Polymers 0.000 claims abstract description 8
- 229920000573 polyethylene Polymers 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 230000009471 action Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 210000004087 cornea Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- 201000004569 Blindness Diseases 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 2
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011587 new zealand white rabbit Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- BKVAAWMQOQLENB-UHFFFAOYSA-N 15-hydroxy stearic acid Chemical compound CCCC(O)CCCCCCCCCCCCCC(O)=O BKVAAWMQOQLENB-UHFFFAOYSA-N 0.000 description 1
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000004420 blood-aqueous barrier Effects 0.000 description 1
- 210000002164 blood-aqueous barrier Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 201000003086 pulmonary systemic sclerosis Diseases 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Abstract
本发明实施例公开了一种抑制角膜基质纤维化的温敏性水凝胶及其制备方法。其制备方法包括:将聚乙二醇‑15羟基硬脂酸酯和雷公藤红素溶解于有机溶剂中,得混合液;在超声搅拌下,将所得混合液滴加到注射用水中,旋蒸除去有机溶剂,得载药聚合物胶束;将所述载药聚合物胶束和温敏性聚合物水凝胶进行配料,混匀后,补加注射用水,即得雷公藤红素温敏性水凝胶。本发明提供的雷公藤红素温敏性水凝胶能够提高药物水溶性、延长其作用时间、可在手术过程中注射并有效抑制角膜基质纤维化。
Description
技术领域
本发明实施例涉及药物制剂技术领域,具体涉及一种抑制角膜基质纤维化的温敏性水凝胶及其制备方法。
背景技术
我国角膜盲患者约500万,是我国第二大致盲性眼病,给患者及家庭带来沉重的经济和精神负担,给国家带来巨大的社会负担。角膜外伤、手术、感染等均可导致角膜基质纤维化。角膜基质纤维化是角膜盲的最常见表现形式,可导致视力下降,也是板层角膜移植术后影响视力的重要原因之一。临床上尚无被批准的可逆转纤维化的药物,为减轻角膜瘢痕形成,目前主要局部用药包括糖皮质激素和丝裂霉素C。但长期应用会引起并发性白内障、继发性青光眼,甚至角巩膜溶解。药物治疗失败时,需要角膜移植手术干预。角膜移植尤其是板层角膜移植术后,角膜基质层间纤维化可明显影响术后视力。因此,深入理解角膜基质纤维化的发生机理,探寻有效的防治措施,是眼科工作者亟待解决的重要难题;积极有效的干预角膜基质纤维化的发生、发展,对角膜盲的预防具有重要的理论意义,对我国的防盲、治盲工作具有重大的社会意义。
雷公藤红素(Celastrol)是从中药雷公藤中提取的生物活性单体,其分子式为C29H38O4,分子量为450.61。雷公藤红素具有抗炎、抗肿瘤、抑制新生血管和肥胖等多种生物学活性,显示强大的生物学功能。研究显示,雷公藤红素抑制在博来霉素诱导的大鼠肺纤维化和系统性硬化,可有效抑制肾脏和肝脏纤维化。雷公藤红素显示强大的抗炎和抗纤维化活性。在角膜基质纤维化的研究中未见雷公藤红素抑制角膜基质纤维化的研究报道。尽管雷公藤红素具有较强大的生物活性,具备抗组织纤维化的潜在药物,但其极差的水溶性限制了其进一步应用。如何增强其水溶性,提高其生物利用度是研究者要解决的首要难题。
眼部给药存在独特的三大屏障:泪膜、角膜和血液-房水屏障,使得局部点药这种给药方式的生物利用度小于5%,造成药物治疗效果欠佳。如何提高眼部靶组织的药物浓度,一直是药学研究的热点和难点,也是眼科亟待解决的关键难题。目前尚未发现将其药物制剂应用到术中以抑制角膜基质纤维化的报道。
发明内容
为此,本发明实施例提供一种抑制角膜基质纤维化的负载雷公藤红素的温敏性水凝胶及其制备方法,该温敏性水凝胶能够提高药物水溶性、延长其作用时间、可在手术过程中注射并有效抑制角膜基质纤维化。
为实现上述目的,本发明采取的技术方案如下:
根据本发明实施例的第一方面,本发明提供一种抑制角膜基质纤维化的温敏性水凝胶的制备方法,包括:
将聚乙二醇-15羟基硬脂酸酯和雷公藤红素溶解于有机溶剂中,得混合液;
在超声搅拌下,将所的混合液滴加到注射用水中,旋蒸除去有机溶剂,得载药聚合物胶束;
将所述载药聚合物胶束和温敏性聚合物水凝胶进行配料,混匀后,补加注射用水,即得雷公藤红素温敏性水凝胶。
作为优选,所述聚乙二醇-15羟基硬脂酸酯、雷公藤红素和有机溶剂的用量配比为10g:(0.1-1.5)g:(2-20)mL。
作为优选,所述有机溶剂为浓度95%以上的乙醇溶液。
作为优选,所述注射用水的用量为所述有机溶剂体积的5-15倍。
作为优选,将0.05-5g所述载药聚合物胶束和1-50g温敏性聚合物水凝胶进行配料,混匀后,补加注射用水定容至100mL。
作为优选,所述温敏性聚合物水凝胶选自泊洛沙姆水凝胶、聚异丙基丙烯酰胺水凝胶、聚甲基丙烯酸-2-(N,N-二甲氨基)乙酯水凝胶、聚乙二醇水凝胶、壳聚糖基聚合物水凝胶中的一种或几种。优选壳聚糖基聚合物水凝胶(TSG),其可按现有技术制备,比如参考文献ACS Applied Materials&Interfaces 2021,13,49369-49379。
在一些具体的实施例中,本发明提供的温敏性水凝胶制剂的制备方法包括以下步骤:
将10g聚乙二醇-15羟基硬脂酸酯和0.8g雷公藤红素溶解于10mL无水乙醇中,得混合液;
在超声搅拌下,将所得混合液滴加到100mL注射用水中,旋蒸除去无水乙醇,得载药聚合物胶束;
将1g所述载药聚合物胶束和1.8g温敏性聚合物水凝胶进行配料,混匀后,补加注射用水定容至100mL,即得雷公藤红素温敏性水凝胶。
本发明发现,在上述投料比下制成的雷公藤红素温敏性水凝胶具有较高的载药量和包封率,同时还具有最佳抑制角膜基质纤维化的作用。
根据本发明实施例的第二方面,本发明提供上述制备方法制成的抑制角膜基质纤维化的温敏性水凝胶。
本发明实施例具有如下优点:
雷公藤红素水溶性极差,37℃在水中的溶解度仅为3.8微克每毫升,现有技术中尚无将其制成可注射制剂、用于术中以抑制角膜基质纤维化。本发明采用纳米技术,首先制备负载雷公藤红素的纳米胶束,以增强其表观溶解度,再将雷公藤红素纳米胶束与温敏性聚合物水凝胶自组装,形成载药、可注射的负载雷公藤红素纳米胶束的温敏性水凝胶,在板层角膜移植术中将其注射于角膜植床上,形成薄层透明凝胶,实现药物雷公藤红素在靶组织的缓慢释放。
附图说明
图1为本发明提供的雷公藤红素温敏性水凝胶在不同温度下的外观性能(A),及动物实验结果(B、C和D)。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式,熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
本实施例提供一种雷公藤红素温敏性水凝胶,其制备方法包括:
(1)称取10g聚乙二醇15-羟基硬脂酸酯和0.8g雷公藤红素,共同溶解于10mL无水乙醇中;
(2)在超声搅拌下,将步骤(1)所得混合液滴加到100mL注射用水中,旋蒸除去无水乙醇,得载药聚合物胶束;
(3)将1g步骤(2)所得载药聚合物胶束和1.8g壳聚糖基聚合物水凝胶(TSG)进行配料,混匀后,补加注射用水定容至100mL,即得。
本实施例制备的雷公藤红素温敏性水凝胶在体外低温环境(20℃)为液态,温度升高至体温水平(32℃)后变为固态(参见图1A)。
实施例2
与实施例1的不同之处在于:雷公藤红素的用量为1.5g,其它同实施例1。
本实施例制备的雷公藤红素温敏性水凝胶在不同温度下的外观性能与实施例1无显著性差异。
实施例3
与实施例1的不同之处在于:雷公藤红素的用量为0.1g,其它同实施例1。
本实施例制备的雷公藤红素温敏性水凝胶在不同温度下的外观性能与实施例1无显著性差异。
动物试验
采用实施例1制备的雷公藤红素温敏性水凝胶,以新西兰白兔板层角膜移植为动物模型,评估雷公藤红素温敏性水凝胶的抗角膜基质纤维化效果。具体方法参照已发表文章(ACS Applied Bio Materials 2021 4(4),3579-3586),详细步骤如下:
3%戊巴比妥钠盐溶液耳缘静脉注射诱导新西兰白兔全身麻醉,剂量按3ml/kg计算。碘伏消毒眼周,聚维酮碘消毒后无菌生理盐水5ml冲洗术眼结膜囊,0.5%盐酸丙美卡因滴眼液进行眼表局部麻醉。显微镜下制作6mm角膜植床,角膜植床滴入实施例1的雷公藤红素温敏性水凝胶2微升,将备好的6.25mm的角膜移植片覆盖于被附水凝胶的植床上,10-0尼龙缝线间断缝合8针。术毕加替沙星眼用凝胶涂于结膜囊内,预防感染。手术均在动物右眼进行。术后实验动物每天结膜囊局部点眼妥布霉素地塞米松滴眼液,一天三次,一次一滴,共七天,以预防急性角膜移植排斥反应。实验动物分三组:第一组术中角膜植床上注射实施例1的雷公藤红素温敏性水凝胶,即负载雷公藤红素的壳聚糖基温敏水凝胶(TSG/CEL),第二组术中角膜植床上注射不负载任何药物的壳聚糖基聚合物水凝胶(TSG),第三组术中角膜植床上注射生理盐水为空白对照。术后每天裂隙灯下观察动物手术眼,记录角膜、前房及眼部情况。观察期为8周。实验结束后使用空气栓塞法处死白兔,方法为耳缘静脉注射20-40ml空气。留取动物眼球标本固定,进行HE和Masson染色。
动物实验结果显示:
各组角膜均未发生排斥和术后感染,各组前节未见明显的炎症,晶状体透明。对照组角膜植片层间混浊,TSG/CEL组角膜植片透明(图1B);HE显示对照组及TSG组角膜基质紊乱,TSG/CEL组角膜基质排列规则(图1C);对角膜基质胶原进一步行Masson染色,显示TSG/CEL组明显抑制角膜基质胶原合成,与空白对照组及TSG组相比,差别具统计学意义(P<0.05)(图1D)。结果显示,板层角膜移植层间注射雷公藤红素温敏性水凝胶,可明显抑制角膜基质纤维化。
综上,雷公藤红素为疏水性药物,本发明先采用聚乙二醇-15羟基硬脂酸酯为载体,制备负载雷公藤红素的纳米胶束,以提高其表观溶解度;再将之溶于壳聚糖基聚合物水凝胶中,制备负载雷公藤红素纳米胶束的温敏性水凝胶(TSG/CEL),其在体外低温环境中为液态,温度升高至体温水平后变为固态,可采用术中直接注射入板层角膜移植植床的给药方式,使雷公藤红素续缓慢作用于局部,提高了雷公藤红素的生物利用度。动物实验表明,本发明的可注射雷公藤红素温敏性水凝胶(TSG/CEL)可明显减轻板层角膜移植术后角膜基质纤维化程度,具有较好的抑制角膜基质纤维化效果。
虽然,上文中已经用一般性说明及具体实施例对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
Claims (8)
1.一种抑制角膜基质纤维化的温敏性水凝胶的制备方法,其特征在于,包括:
将聚乙二醇-15羟基硬脂酸酯和雷公藤红素溶解于有机溶剂中,得混合液;
在超声搅拌下,将所得混合液滴加到注射用水中,旋蒸除去有机溶剂,得载药聚合物胶束;
将所述载药聚合物胶束和温敏性聚合物水凝胶进行配料,混匀后,补加注射用水,即得雷公藤红素温敏性水凝胶。
2.根据权利要求1所述的抑制角膜基质纤维化的温敏性水凝胶的制备方法,其特征在于,所述聚乙二醇-15羟基硬脂酸酯、雷公藤红素和有机溶剂的用量配比为10g:(0.1-1.5)g:(2-20)mL。
3.根据权利要求2所述的抑制角膜基质纤维化的温敏性水凝胶的制备方法,其特征在于,所述有机溶剂为浓度95%以上的乙醇溶液。
4.根据权利要求1-3任一项所述的抑制角膜基质纤维化的温敏性水凝胶的制备方法,其特征在于,所述注射用水的用量为所述有机溶剂体积的5-15倍。
5.根据权利要求4所述的抑制角膜基质纤维化的温敏性水凝胶的制备方法,其特征在于,将0.05-5g所述载药聚合物胶束和1-50g温敏性聚合物水凝胶进行配料,混匀后,补加注射用水定容至100mL。
6.根据权利要求5所述的抑制角膜基质纤维化的温敏性水凝胶的制备方法,其特征在于,所述温敏性聚合物水凝胶选自泊洛沙姆水凝胶、聚异丙基丙烯酰胺水凝胶、聚甲基丙烯酸-2-(N,N-二甲氨基)乙酯水凝胶、聚乙二醇水凝胶、壳聚糖基聚合物水凝胶中的一种或几种。
7.根据权利要求1所述的抑制角膜基质纤维化的温敏性水凝胶的制备方法,其特征在于,所述方法包括以下步骤:
将10g聚乙二醇-15羟基硬脂酸酯和0.8g雷公藤红素溶解于10mL无水乙醇中,得混合液;
在超声搅拌下,将所得混合液滴加到100mL注射用水中,旋蒸除去无水乙醇,得载药聚合物胶束;
将1g所述载药聚合物胶束和1.8g温敏性聚合物水凝胶进行配料,混匀后,补加注射用水定容至100mL,即得雷公藤红素温敏性水凝胶。
8.一种抑制角膜基质纤维化的温敏性水凝胶,其特征在于,由权利要求1-7任一项所述的制备方法制成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210013121.4A CN114392229A (zh) | 2022-01-06 | 2022-01-06 | 一种抑制角膜基质纤维化的温敏性水凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210013121.4A CN114392229A (zh) | 2022-01-06 | 2022-01-06 | 一种抑制角膜基质纤维化的温敏性水凝胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114392229A true CN114392229A (zh) | 2022-04-26 |
Family
ID=81230015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210013121.4A Pending CN114392229A (zh) | 2022-01-06 | 2022-01-06 | 一种抑制角膜基质纤维化的温敏性水凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114392229A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101342142A (zh) * | 2008-07-24 | 2009-01-14 | 北京大学 | 一种可注射的温敏原位凝胶制剂,它们的制备方法及其应用 |
CN102973636A (zh) * | 2011-05-25 | 2013-03-20 | 江西中医学院 | 雷公藤微乳凝胶制剂及其制备方法 |
CN106214682A (zh) * | 2016-09-06 | 2016-12-14 | 河南省眼科研究所 | 雷公藤红素在制备抗角膜移植排斥滴眼液制剂中的应用 |
-
2022
- 2022-01-06 CN CN202210013121.4A patent/CN114392229A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101342142A (zh) * | 2008-07-24 | 2009-01-14 | 北京大学 | 一种可注射的温敏原位凝胶制剂,它们的制备方法及其应用 |
CN102973636A (zh) * | 2011-05-25 | 2013-03-20 | 江西中医学院 | 雷公藤微乳凝胶制剂及其制备方法 |
CN106214682A (zh) * | 2016-09-06 | 2016-12-14 | 河南省眼科研究所 | 雷公藤红素在制备抗角膜移植排斥滴眼液制剂中的应用 |
Non-Patent Citations (3)
Title |
---|
LEI JIANG ET AL: "Tripterine emerges as a potential anti-scarring agent in NIH/3T3 cells by repressing ANRIL", GEN. PHYSIOL. BIOPHYS., vol. 39, pages 355 - 362 * |
LI-PING WANG ET AL: "Celastrol inhibits migration, proliferation and transforming growth factor-β2-induced epithelial-mesenchymal transition in lens epithelial cells", INT J OPHTHALMOL, vol. 12, no. 10, pages 1517 - 1523 * |
刘敏华 等: "合成高分子基温敏水凝胶在眼病治疗中的研究进展", 高分子学报, vol. 52, no. 1, pages 47 - 60 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102496234B1 (ko) | 녹내장 수술 성공을 개선하기 위해 닌테다닙을 사용하는 조성물 및 방법 | |
CN105073153B (zh) | 含有前列腺胺的眼内植入物 | |
CN103002884A (zh) | 用前房内比马前列素植入物的眼内压降低 | |
Sun et al. | Sustained subconjunctival delivery of cyclosporine A using thermogelling polymers for glaucoma filtration surgery | |
JP2022180505A (ja) | 眼科用薬剤組成物、眼科用キット、及びその医学的応用 | |
Einmahl et al. | A new poly (ortho ester)-based drug delivery system as an adjunct treatment in filtering surgery | |
Han et al. | Effects of bevacizumab loaded PEG-PCL-PEG hydrogel intracameral application on intraocular pressure after glaucoma filtration surgery | |
EP0443809A2 (en) | Coated intraocular lens and coatings therefor | |
CN114392229A (zh) | 一种抑制角膜基质纤维化的温敏性水凝胶及其制备方法 | |
CN114533703A (zh) | 一种雷公藤红素复合膜及其制备方法和应用 | |
EP4052694A1 (en) | Eye drop composition for preventing or treating eye disease | |
CN114392230A (zh) | 雷公藤红素在制备抑制角膜基质纤维化药物中的应用 | |
CA3088185C (en) | Suspension compositions of multi-target inhibitors | |
Wang et al. | Safety and efficacy of intracapsular tranilast microspheres in experimental posterior capsule opacification | |
Kaushal et al. | Nanocarriers Based Ocular Therapeutics: Updates, Challenges and Future Prospectives | |
RU2284181C2 (ru) | Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк" | |
CN110960485A (zh) | 一种用于治疗角膜炎的药物及其制备方法 | |
Zheng et al. | Recent Advances in Ocular Therapy by Hydrogel Biomaterials | |
CN116172885A (zh) | 一种抗后发性白内障药物制剂及其制备方法 | |
KR20200137706A (ko) | 안질환 치료용 조성물 | |
JPH03236324A (ja) | 血管新生阻害剤 | |
CN117752617A (zh) | 两亲性阳离子物质修饰的mPEG-PCL纳米颗粒在制备治疗视网膜疾病的药物中的应用 | |
CN100368021C (zh) | 一种含眼科用抗增殖性药物的海藻酸钠微胶珠和凸膜及制备方法 | |
CN116509993A (zh) | 一种用于防治视网膜病的药物及其制备方法 | |
CN115282145A (zh) | 青蒿琥酯在制备治疗青光眼的药物或制剂中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |